Intellipharmaceutics

30 Worcester Road
Toronto
Ontario
M9W 5X2
Canada

Tel: 416-798-3001
Fax: 416-798-3007

Email: contact@intellipharmaceutics.com

Show jobs for this employer

157 articles with Intellipharmaceutics

  • Intellipharmaceutics International Inc., a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, reported the results of operations for the three and nine months ended August 31, 2022.

  • Intellipharmaceutics International Inc announced that it has entered into a license and supply agreement with Taro Pharmaceuticals Inc., by which the Company has granted Taro an exclusive license to market, sell and distribute in Canada, Desvenlafaxine Extended-release Tablets in the 50 mg and 100 mg strengths approved for sale in the Canadian market by the Pharmaceutical Drugs Directory of Health Canada.

  • Intellipharmaceutics International Inc., a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, reported the results of operations for the three and six months ended May 31, 2022.

  • Intellipharmaceutics International Inc. announced today that its financial statements for the interim period ended May 31, 2022 and related management's discussion due July 15, 2022 (the "Filing Deadline") will not be filed by the Filing Deadline.

  • Intellipharmaceutics International Inc. reports, as required by TSX rules, that the five nominees, each of whom was an incumbent director of the Company, identified in the Management Information Circular dated April 12, 2022 were elected as directors of the Company at the annual meeting of shareholders of the Company.

  • Intellipharmaceutics International Inc. and, a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, reported the results of operations for the three months ended February 28, 2022.

  • Intellipharmaceutics International Inc., a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, reported the results of operations for the year ended November 30, 2021.

  • Intellipharmaceutics International Inc. and, a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, announced with great sadness that Kenneth Keirstead, a member of the Company's Board of Directors, has passed away.

  • Intellipharmaceutics International Inc. is issuing this press release in response to a request from the Investment Industry Regulatory Organization of Canada to comment on the recent trading activity of its stock.

  • Intellipharmaceutics International Inc. and, a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, reported the results of operations for the three and nine months ended August 31, 2021.

  • Intellipharmaceutics International Inc., a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, reported the results of operations for the three and six months ended May 31, 2021.

  • Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI) a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, is pleased to announce the completion of a non-brokered private placement of 9,414,560 common shares of the Company

  • Intellipharmaceutics International Inc. a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three months ended February 28, 2021.

  • Intellipharmaceutics International Inc. and, a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, reported the results of operations for the year ended November 30, 2020.

  • Intellipharmaceutics International Inc. (OTCQB:IPCIF) (TSX:IPCI) a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, reports, as required by TSX rules, that the six nominees, each of whom was an incumbent director of the Company, identified in the Management Information Circular

  • Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, announced today that, due to the ongoing COVID-19 pandemic, it is changing the venue for its Annual General Meeting scheduled to be held on December 23, 202

  • Intellipharmaceutics International Inc. today reported the results of operations for the three and nine months ended August 31, 2020. All dollar amounts referenced herein are in United States dollars unless otherwise noted.

  • Intellipharmaceutics International Inc., a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three and six months ended May 31, 2020. All dollar amounts referenced herein are in United States dollars unle

  • Intellipharmaceutics International Inc. (OTCQB:IPCIF) (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, announced today that the parties in the cases, numbers 17-cv-392-RGA, 18-cv-404-RGA and 20-cv-515-RGA (the "Litigations") between Purdue Pharma L.P. e

  • Intellipharmaceutics International Inc. today announced that it has submitted an investigational new drug ("IND") application to the U.S. Food and Drug Administration ("FDA") for its oxycodone hydrochloride immediate release ("IPCI006") tablets in the 5 mg, 10 mg, 15 mg, 20 mg and 30 mg strengths.